GRI:ARCA-Cohen & Steers Global Realty Majors (USD)

ETF | Biotechnology | NYSE Arca

Last Closing

USD 0.876

Change

-0.07 (-7.79)%

Market Cap

USD 0.09B

Volume

0.83M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks investment results that correspond generally to the performance, before the fund's fees and expenses, of an index called the Cohen & Steers Global Realty Majors Index. The fund will normally invest at least 90% of its total assets in common stocks and other equity securities (which may include ADRs, ADSs and GDRs) that comprise the underlying index. The underlying index consists of the largest and most liquid securities within the global real estate universe that the index provider believes are likely to lead the global securitization of real estate. The fund is non-diversified.

Inception Date: 07/05/2008

Primary Benchmark: Cohen & Steers Gbl Realty Majr TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.55%

Management Expense Ratio: 0.55 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Biotechnology

Symbol Name Mer Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc 0.00 %

-15.02 (-2.91%)

USD 121.60B
REGN Regeneron Pharmaceuticals Inc 0.00 %

-2.74 (-0.33%)

USD 92.70B
ALNY Alnylam Pharmaceuticals Inc 0.00 %

+2.39 (+0.86%)

USD 35.78B
ARGX argenx NV ADR 0.00 %

-7.06 (-1.18%)

USD 35.64B
BGNE BeiGene Ltd 0.00 %

-0.43 (-0.21%)

USD 22.85B
MRNA Moderna Inc 0.00 %

-4.08 (-8.71%)

USD 21.00B
UTHR United Therapeutics Corporatio.. 0.00 %

-9.56 (-2.33%)

USD 16.70B
RPRX Royalty Pharma Plc 0.00 %

+0.15 (+0.57%)

USD 16.11B
INCY Incyte Corporation 0.00 %

-1.85 (-2.22%)

USD 14.67B
SMMT Summit Therapeutics PLC 0.00 %

+0.36 (+1.68%)

USD 13.75B

ETFs Containing GRI

UKPH:XETRA iShares UK Property UCITS.. 3.23 % 0.00 %

+0.01 (+0.17%)

N/A
IUKP:LSE iShares UK Property UCITS 3.10 % 0.00 %

+0.30 (+0.17%)

USD 0.58B
UKRE:LSE iShares MSCI Target UK Re.. 2.46 % 0.00 %

+1.05 (+0.17%)

USD 0.12B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 127.53% 64% D 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 127.53% 64% D 82% B
Trailing 12 Months  
Capital Gain -31.02% 19% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.02% 19% F 20% F
Trailing 5 Years  
Capital Gain -98.17% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.17% 3% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -31.55% 12% F 7% C-
Dividend Return -31.55% 12% F 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.51% 68% D+ 41% F
Risk Adjusted Return -69.32% 16% F 10% F
Market Capitalization 0.09B N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector